• According to reports, the departure of two lead FDA vaccine officials marks a dispute between FDA and CDC
• Some inside FDA have reportedly complained that CDC has improperly jumped ahead of FDA on some contentious Covid-19 vaccine issues, such as approving boosters and recommending shots for children

The following is an excerpt from an article in Endpoints News, which reports on pharmaceutical industry news.

Two of the FDA’s most senior vaccine leaders are exiting from their positions, raising fresh questions about the Biden administration and the way that it’s sidelined the FDA.

Marion Gruber, director of the FDA’s Office of Vaccines Research & Review and 32-year veteran of the agency, will leave at the end of October, and OVRR deputy director Phil Krause, who’s been at FDA for more than a decade, will leave in November. The news, first reported by BioCentury, is a massive blow to confidence in the agency’s ability to regulate vaccines.

The bombshell announcement comes at a particularly crucial moment, as boosters and children’s shots are being weighed by the regulator. The departures also come as the administration has recently jumped ahead of the FDA’s reviews of booster shots, announcing that they might be available by the week of Sept. 20. (Continued…)

Read the rest of the article here.